Why is CELC's stock going up?

The stock price of CELC has experienced an increase from July 28 to July 29. Celcuity's stock is likely to be rising today due to several positive developments: 1. **Positive Clinical Trial Results**: Celcuity reported positive topline results from its Phase 3 VIKTORORIA-1 clinical trial for gedatolisib in combination with palbociclib and fulvestrant for advanced HR+/HER2- breast cancer without PIK3CA mutations. This demonstrates significant efficacy in treating this specific patient population. 2. **Upcoming FDA Submission**: The company plans to submit a New Drug Application (NDA) to the FDA in the fourth quarter based on these topline results, which could lead to accelerated approval due to the Breakthrough Therapy Designation granted by the FDA. 3. **Expansion of Addressable Market**: The multi-indication strategy for gedatolisib could expand the addressable market significantly, as the drug is being evaluated in several clinical trials for different solid tumor indications. 4. **Analyst Ratings and Price Target Increase**: H.C. Wainwright raised the price target on Celcuity to $50 from $27, reflecting confidence in the company's future prospects. 5. **Public Offerings and Strategic Financing**: Celcuity announced proposed public offerings totaling $225 million, which include $150 million in convertible senior notes due 2031 and $75 million in common stock. This financing could provide the necessary capital to support ongoing clinical trials and research & development activities. These factors have likely contributed to the recent increase in Celcuity's stock price, indicating positive market sentiment towards the company's future prospects. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |CELC|CELC.O|Celcuity|20250725|-1.9929|186| |CELC|CELC.O|Celcuity|20250728|167.175|186| |CELC|CELC.O|Celcuity|20250729|4.648|186|